A new class of cancer drugs known as histone deacetylases inhibitors, or HDACs, may also treat autoimmune diseases such as rheumatoid arthritis and Crohn's disease, scientists report. In testing Merck's skin cancer treatment Zolinza, the researchers found that the drug enhanced the production of cells that regulate the immune system in mice, preventing inflammatory bowel disease and the rejection of heart transplants.

Full Story:

Related Summaries